SLFN11 and cancer: To further investigate such a potential link between SLFN11 cancer immunity and DDA treatment, we performed total RNA sequencing of SLFN11-proficient (DU145 wild type, WT) and SLFN11-deficient (DU145 SLFN11 knockout, KO) cells treated for 0, 6, or 24 hours with gemcitabine, a DNA synthesis inhibitor that acts primarily during the S-phase of the cell cycle and induces replication stress (39).